- Clinical Trials
- December 2019
- 383 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Drug Pipelines
- September 2020
- 1216 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- October 2023
- 108 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- May 2022
- 600 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- May 2022
- 125 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- November 2023
- 178 Pages
Global
From €2689EUR$2,799USD£2,309GBP
Mesothelioma is a rare form of cancer that affects the lining of the lungs, abdomen, and heart. It is caused by exposure to asbestos and is difficult to treat. Oncology drugs are used to treat mesothelioma, including chemotherapy, radiation therapy, and targeted therapy. Targeted therapy is a newer form of treatment that uses drugs to target specific molecules in cancer cells, which can help slow the growth of the cancer.
The mesothelioma drug market is a rapidly growing segment of the oncology drug market. It is driven by the increasing prevalence of mesothelioma, as well as the development of new treatments. Companies in the mesothelioma drug market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. These companies are developing new drugs to treat mesothelioma, as well as providing existing treatments. Show Less Read more
